A peculiar-looking new psilocybin mushroom strain has been catching the eye of mycology and psychedelics enthusiasts. It has no gills, looks nothing like other varieties of magic mushrooms and will turn blue if you touch it.
Spore syringes needed to grow “Snowball Cubensis” are exclusively available through IncolulateTheWorld (ITW). The strain was discovered by mycologist Pope Joseph when he noticed a mutation while cultivating a batch of Penis Envy psychedelic fungi.
He then spent over two and a half years isolating the novel strain so that he could share it with the world. This was an extensive process with thousands of Petri dishes.
“ITW Snowball has been tested for thousands of variables, waiting to be released until true stability was achieved, and we are thrilled to say we got what we were looking for,” the Seattle-based mushroom spore business said.
Each psychoactive puffball can grow to be the size of a softball.
“Snowball is like no other strain of cubensis we’ve seen before, making it the perfect addition for any researcher seeking something new and exciting,” ITW proclaimed.
Golden Teacher, Blue Meanie and Stargazer are some of the other strains that the Washington company sells spores for. ITW’s website also features a blog covering multiple mycology topics.
Photo credit: InoculateTheWorld
Read more: Tacoma joins Seattle in making psychedelics law enforcement lowest priority
Read more: Psychedelic YouTuber Willy Myco drops world’s first LSD synthesizing tutorial vid
ITW founder manages psychedelic therapeutics company
Aside from creating a successful psilocybin spore distributor, ITW founder Andrew Collins is currently a Managing Partner at 5DG Therapeutics.
This biotech company is based out of the Mcknight Brain Institute at the University of Florida. It specializes in investigating psychedelic treatments for brain health disorders, particularly focusing on psilocybin.
5DG also has a partnership with Casa Sollievo della Sofferenza — a private scientific research hospital in Italy.
Collins says that 5DG’s Chief Science Officer, Dr. Brent Reynolds, has invented a patent-pending system that can bypass peripheral metabolism and the blood-brain barrier to deliver drugs directly to the central nervous system.
Reynolds is renowned for his stem cell research and multiple contributions to peer-reviewed science journals. He has been a professor at the University of Florida for 17 years.
rowan@mugglehead.com
